Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Virpax Pharmaceuticals, Inc. - Common Stock (NQ:VRPX)

0.6695 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Virpax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Virpax Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis
From Virpax Pharmaceuticals
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 9, 2022
Upgrades 
Via Benzinga
Virpax Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows. 
Via Benzinga
Virpax Pharma Expands AnQlar Worldwide Licensing Pact In COVID-19
Virpax Pharmaceuticals Inc (NASDAQ: VRPX)  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Virpax Pharmaceuticals Reports 2022 First Quarter Results and Recent Developments
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
24 Stocks Moving in Friday's Pre-Market Session
Gainers Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 35% to $3.47 in pre-market trading. Vinco Ventures set record date as May 18, 2022 For dividend of shares related to Cryptyde deal. The dividend... 
Via Benzinga
Virpax Pharmaceuticals Enters Into CRADA With The U.S. Army Institute of Surgical Research
From Virpax Pharmaceuticals, Inc.
Via Business Wire
92 Biggest Movers From Friday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the... 
Via Benzinga
55 Stocks Moving In Friday's Mid-Day Session
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 24.4% to $7.50. Swvl Holdings 13D Filing from investor Ahmed Sabbah showed a new 6.4% stake in the company. 
Via Benzinga
Virpax Successfully Completes Initial Preclinical Studies for VRP324
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
On Friday, 213 companies hit new 52-week lows. 
Via Benzinga
Virpax Pharmaceuticals Reports 2021 Year-End Results
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Completes All FDA-Required Pre-Clinical Studies for Epoladerm™
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
Nanomerics Receives Further Upfront Payment for Anti-Viral Spray AnQlar(TM)
LONDON, UK / ACCESSWIRE / March 22, 2022 / Nanomerics Ltd., a private speciality pharmaceutical company, today announced the receipt of a further milestone payment on agreeing the expansion of its... 
From Nanomerics Ltd
Via AccessWire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Sunshine Biopharma (NASDAQ:SBFM) stock increased by 15.5% to $3.5 during Friday's pre-market session. The company's market cap stands at $15.6 million.... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 92.3% to $44.04 during Tuesday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
Virpax Pharmaceuticals Expands AnQlar™ Development and Commercialization Rights Through Worldwide Licensing Agreement
From Virpax Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Unicycive Therapeutics (NASDAQ:UNCY 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Revelation Biosciences (NASDAQ:REVB 
Via Benzinga
News Outlets Highlight Virpax Pharmaceuticals and Its Potential Solutions for the Opioid Crisis and COVID-19
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Reports Favorable Preclinical Safety Data for Envelta™  for the Treatment of Acute and Chronic Pain
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Altasciences Chosen by Virpax Pharmaceuticals, Inc. to Conduct First-in-Human Study of Epoladerm™ for Chronic Pain Associated with Osteoarthritis of the Knee
From Altasciences and Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax® Successfully Completes Preclinical Dermal Safety Studies for Epoladerm™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows. Noteable 52-Week Lows: Intuitive Surgical (NASDAQ:ISRG) is the largest company in terms of market cap to... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers SomaLogic (NASDAQ:SLGC) shares mo... 
Via Benzinga
Virpax® Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee
From Virpax Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.